Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 8

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 8
---
1,420.8% CER). The increase was due to a new launch in the U.S. in November 2023, followed by several other countries, as it addressed a need for new treatment options in metastatic colorectal cancer.

Sales of ADCETRIS (for malignant lymphomas) were JPY 99.6 billion (JPY +15.4 billion and +18.2% AER, +13.5% CER). The increase was led by strong demand in the Growth and Emerging Markets, Europe and Canada, primarily driven by increased use in the first line Hodgkin lymphoma, as well as favorable foreign exchange rates.

Sales of LEUPLIN/ENANTONE (for endometriosis, uterine fibroids, premenopausal breast cancer, prostate cancer, and other certain indications) were JPY 89.2 billion (JPY +9.5 billion and +11.9% AER, +8.5% CER). The increase was primarily due to the sales increase in the U.S. the Growth and Emerging Markets, as well as favorable foreign exchange rates.

Sales of ICLUSIG (for leukemia) were JPY 54.8 billion (JPY +13.3 billion and +32.2% AER, +24.9% CER). The increase was due to the U.S. label expansion for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy in March 2024, as well as favorable foreign exchange rates.

#### Vaccines
In Vaccines, revenue was JPY 49.9 billion (JPY +20.4 billion and +69.1% AER, +64.9% CER).

Sales of QDENGA (for prevention of dengue) were JPY 30.0 billion (JPY +24.2 billion and +418.5% AER, +397.4% CER). The increase was due to the expansion of QDENGA availability in endemic countries, with the vaccine now available in over 25 countries including non-endemic countries.

Sales of other vaccine products in aggregate decreased primarily due to the termination of the distribution contract of SPIKEVAX, a COVID-19 vaccine in Japan in March 2024. The decrease was partially mitigated by the sales increase of NUVAXOVID, a COVID-19 vaccine for the Omicron JN.1 variant, approved in